Shimai Pharma Presents DNV3 (LAG-3 Antibody) Combination Therapy Results for Melanoma at ASCO 2025 Annual Meeting

Shimai Pharma Presents SMET12 (EGFR×CD3 Bispecific Antibody) Combination Therapy Results for Advanced NSCLC at ASCO 2025 Annual Meeting

CentryMed to Present Clinical Data on SMET12 and DNV3 at 2025 ASCO Annual Meeting

CentryMed’s Groundbreaking Enzyme-Controlled TCE Technology: Recombinant Human Anti-EGFR-CD3 Bispecific Antibody CMDE005 Receives FDA IND Clearance

International Endorsement, Global Leadership | GPC3×CD3 Bispecific Antibody CMD011 Receives FDA IND Clearance

CentryMed’s DNV3 Combined with Toripalimab and Chemotherapy Phase II Clinical Trial IND Application Approved by NMPA

CentryMed’s Recombinant Human Anti-EGFR-CD3 Enzyme-Controlled Bispecific Antibody Receives Clinical Trial Approval